Podcast Atlas
entity Updated 2026-07-14 Tags: Company, Biotech, Oncology, Y-Combinator

Adventris Pharmaceuticals

Adventris Pharmaceuticals is the biotech startup discussed by Jen Herbach in Founder Mode: Jen Herbach, Founder & CEO, Adventris Pharmaceuticals. The source title calls the company Adventris Pharmaceuticals; the body repeatedly spells it “Adventress.” This page uses the source-title spelling while preserving that mismatch as source context.

The company is described as a Winter 2023 Y Combinator company developing [[CancerVaccinePlatform|cancer vaccines]] that help the immune system recognize cancer cells. Its first target is [[KRASOncologyTarget|KRAS]], which Herbach describes as a driver mutation involved in more than 30% of cancers and especially present in lung, colon, and pancreatic cancer.

The source says Adventris is beginning with localized pancreatic cancer patients and wants eventually to move from treatment into prevention. Herbach says the company is finalizing its patient product, preparing an IND package for the FDA, and aiming to dose first patients in early 2027.

Adventris also becomes a Biotech Founder Control case. Herbach says the company used SAFEs and avoided investor board seats after YC advice, then later used that control to reject investor pressure over scientific strategy and to make a delivery-platform decision without needing external board approval.

Key Claims

  • Adventris is presented as a cancer-vaccine company, not a general oncology software or services company.
  • Its first strategic target is KRAS because one mutation family could matter across multiple cancer types.
  • The first clinical setting is localized pancreatic cancer, with prevention as the longer-term ambition.
  • Founder control is treated as part of product and science governance because board pressure could change the clinical strategy.

Connections